BRAF and colorectal carcinoma: This is in contrast to the improved outcomes observed with early-stage MSI-H CRC, overall; it is possible that in advanced or late-stage CRC exhibiting MSI-H, BRAF mutations may be the driving force behind these documented poor outcomes [63,66].